Conivaptan: promise of treatment in heart failure.

Article Details

Citation

Copy to clipboard

Hoque MZ, Arumugham P, Huda N, Verma N, Afiniwala M, Karia DH

Conivaptan: promise of treatment in heart failure.

Expert Opin Pharmacother. 2009 Sep;10(13):2161-9. doi: 10.1517/14656560903173237.

PubMed ID

19663609 [ View in PubMed

]

Abstract

Conivaptan, the first vasopressin receptor antagonist approved by the FDA, is available for the treatment of hyponatremia in euvolemic and hypervolemic patients. The renin-angiotensin-aldosterone system is activated in heart failure (HF) causing clinical worsening. Arginine vasopressin levels are also elevated in HF. Conivaptan is an effective and FDA approved for the treatment of euvolemic and hypervolemic hyponatremia and may offer an extra treatment option in HF by targeting V(1a) and V(2) receptors. In this article we review the physiology, preclinical studies as well as the human clinical studies on the use of conivaptan and its potential and promise in the treatment of HF.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Conivaptan	Vasopressin V1a receptor	Protein	Humans	Yes	Antagonist	Details
Conivaptan	Vasopressin V2 receptor	Protein	Humans	Yes	Antagonist	Details